High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors
Malignant transformation of cells is associated with downregulation of HLA class I APM components in most of the tumors. These defects are clinically relevant, since they are frequently associated with the clinical course of the disease. Only in a few tumors malignancy is associated with the upregul...
Gespeichert in:
Veröffentlicht in: | Journal for immunotherapy of cancer 2013-11, Vol.1 (S1), p.P264-P264, Article P264 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | P264 |
---|---|
container_issue | S1 |
container_start_page | P264 |
container_title | Journal for immunotherapy of cancer |
container_volume | 1 |
creator | Grizzi, Fabio Franceschini, Barbara Biccari, Sonia Di Bossi, Paola Chiriva-Internati, Maurizio Ferrone, Soldano |
description | Malignant transformation of cells is associated with downregulation of HLA class I APM components in most of the tumors. These defects are clinically relevant, since they are frequently associated with the clinical course of the disease. Only in a few tumors malignancy is associated with the upregulation of HLA class I antigens. Among them is hepatocellular carcinoma (HCC). The frequency of HLA class I APM component upregulation and its clinical significance in HCC are not known. These topics were investigated in the present study, since the resulting information may contribute to assess the therapeutic efficacy of T cell-based immunotherapy for the treatment of HCC. Twenty-one surgically resected primary HCC tumors and autologous adjacent non-malignant tissues were stained with a unique panel of monoclonal antibodies which recognize HLA class I APM components. The staining patterns of the malignant tumors were compared to those of the autologous non malignant tissues. To assess the functional significance of changes in HLA class I APM component expression in HCC tumors, the results of immunohistochemical staining were correlated with the extent of CD8+ cytotoxic T-lymphocyte infiltrate, quantified with a computer-aided image analysis system. In all the HCC tumors, malignant hepatocytes expressed high levels of HLA class I APM components. In contrast these molecules were not detected in normal hepatocytes, although they displayed a low expression in some apparently normal hepatocytes adjacent to the HCC tumor. The HLA class I APM component upregulation in HCC was associated with the extent of CD8+ T cell infiltrate, although this association did not reach the level of statistical significance. Our results corroborate the information in the literature about the lack of HLA class I antigen expression in hepatocytes. Furthermore our study shows for the first time that APM components are also not detectable in normal hepatocytes. Lastly our study shows that HLA class I APM component upregulation is very frequent in HCC. Its association with T cell infiltrate, although not statistically significant, is compatible with the possibility that HCC cells are recognized by CD8+ T cells. If so, HCC should represent an attractive target to apply T cell-based immunotherapy. |
doi_str_mv | 10.1186/2051-1426-1-S1-P264 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3991183</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638096901</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1724-2206e03759f5d886f977f4283914126168e2ca376c2b8d2a8380daf71761c6843</originalsourceid><addsrcrecordid>eNpVUcFKxDAQDaKg6H6Bl4AXPVQzSTdNL8Ii6gorCqvnkM2m3Uib1KQV9uqXm7KL6GmGmTfvPeYhdA7kGkDwG0qmkEFOeQbZErJXyvMDdPI7PfzTH6NJjB-EECCMCSFO0Pfc1htcBfM5GKe32Fd4vphh3agY8RNWrre1cbgLXpsYratxq_TGOhO2-HL2-nyFtW8774zr8dAFUw-N6q132I5HtlUJtzGd6tN906RlwFoFbZ1vFe6H1od4ho4q1UQz2ddT9P5w_3Y3zxYvj093s0WmoaB5RinhhrBiWlbTtRC8KouiyqlgJeRAOXBhqFas4JquxJoqwQRZq6qAgoPmImen6HbH2w2r1qx1shxUI_cupVdW_t84u5G1_5KsLNOjWSK42BMEn94Ve_nhh-CSZ0l5Uit5SSCh2A6lg48xmOpXAYgcA5NjHHKMQ4JcghwDYz8Lx4pm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638096901</pqid></control><display><type>article</type><title>High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors</title><source>BMJ Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Grizzi, Fabio ; Franceschini, Barbara ; Biccari, Sonia Di ; Bossi, Paola ; Chiriva-Internati, Maurizio ; Ferrone, Soldano</creator><creatorcontrib>Grizzi, Fabio ; Franceschini, Barbara ; Biccari, Sonia Di ; Bossi, Paola ; Chiriva-Internati, Maurizio ; Ferrone, Soldano</creatorcontrib><description>Malignant transformation of cells is associated with downregulation of HLA class I APM components in most of the tumors. These defects are clinically relevant, since they are frequently associated with the clinical course of the disease. Only in a few tumors malignancy is associated with the upregulation of HLA class I antigens. Among them is hepatocellular carcinoma (HCC). The frequency of HLA class I APM component upregulation and its clinical significance in HCC are not known. These topics were investigated in the present study, since the resulting information may contribute to assess the therapeutic efficacy of T cell-based immunotherapy for the treatment of HCC. Twenty-one surgically resected primary HCC tumors and autologous adjacent non-malignant tissues were stained with a unique panel of monoclonal antibodies which recognize HLA class I APM components. The staining patterns of the malignant tumors were compared to those of the autologous non malignant tissues. To assess the functional significance of changes in HLA class I APM component expression in HCC tumors, the results of immunohistochemical staining were correlated with the extent of CD8+ cytotoxic T-lymphocyte infiltrate, quantified with a computer-aided image analysis system. In all the HCC tumors, malignant hepatocytes expressed high levels of HLA class I APM components. In contrast these molecules were not detected in normal hepatocytes, although they displayed a low expression in some apparently normal hepatocytes adjacent to the HCC tumor. The HLA class I APM component upregulation in HCC was associated with the extent of CD8+ T cell infiltrate, although this association did not reach the level of statistical significance. Our results corroborate the information in the literature about the lack of HLA class I antigen expression in hepatocytes. Furthermore our study shows for the first time that APM components are also not detectable in normal hepatocytes. Lastly our study shows that HLA class I APM component upregulation is very frequent in HCC. Its association with T cell infiltrate, although not statistically significant, is compatible with the possibility that HCC cells are recognized by CD8+ T cells. If so, HCC should represent an attractive target to apply T cell-based immunotherapy.</description><identifier>ISSN: 2051-1426</identifier><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1186/2051-1426-1-S1-P264</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Immunotherapy ; Liver cancer ; Lymphocytes ; Poster Presentation ; Tumors</subject><ispartof>Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P264-P264, Article P264</ispartof><rights>2013 Grizzi et al; licensee BioMed Central Ltd. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2013 Grizzi et al; licensee BioMed Central Ltd. 2013 Grizzi et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991183/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991183/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Grizzi, Fabio</creatorcontrib><creatorcontrib>Franceschini, Barbara</creatorcontrib><creatorcontrib>Biccari, Sonia Di</creatorcontrib><creatorcontrib>Bossi, Paola</creatorcontrib><creatorcontrib>Chiriva-Internati, Maurizio</creatorcontrib><creatorcontrib>Ferrone, Soldano</creatorcontrib><title>High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors</title><title>Journal for immunotherapy of cancer</title><description>Malignant transformation of cells is associated with downregulation of HLA class I APM components in most of the tumors. These defects are clinically relevant, since they are frequently associated with the clinical course of the disease. Only in a few tumors malignancy is associated with the upregulation of HLA class I antigens. Among them is hepatocellular carcinoma (HCC). The frequency of HLA class I APM component upregulation and its clinical significance in HCC are not known. These topics were investigated in the present study, since the resulting information may contribute to assess the therapeutic efficacy of T cell-based immunotherapy for the treatment of HCC. Twenty-one surgically resected primary HCC tumors and autologous adjacent non-malignant tissues were stained with a unique panel of monoclonal antibodies which recognize HLA class I APM components. The staining patterns of the malignant tumors were compared to those of the autologous non malignant tissues. To assess the functional significance of changes in HLA class I APM component expression in HCC tumors, the results of immunohistochemical staining were correlated with the extent of CD8+ cytotoxic T-lymphocyte infiltrate, quantified with a computer-aided image analysis system. In all the HCC tumors, malignant hepatocytes expressed high levels of HLA class I APM components. In contrast these molecules were not detected in normal hepatocytes, although they displayed a low expression in some apparently normal hepatocytes adjacent to the HCC tumor. The HLA class I APM component upregulation in HCC was associated with the extent of CD8+ T cell infiltrate, although this association did not reach the level of statistical significance. Our results corroborate the information in the literature about the lack of HLA class I antigen expression in hepatocytes. Furthermore our study shows for the first time that APM components are also not detectable in normal hepatocytes. Lastly our study shows that HLA class I APM component upregulation is very frequent in HCC. Its association with T cell infiltrate, although not statistically significant, is compatible with the possibility that HCC cells are recognized by CD8+ T cells. If so, HCC should represent an attractive target to apply T cell-based immunotherapy.</description><subject>Immunotherapy</subject><subject>Liver cancer</subject><subject>Lymphocytes</subject><subject>Poster Presentation</subject><subject>Tumors</subject><issn>2051-1426</issn><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVUcFKxDAQDaKg6H6Bl4AXPVQzSTdNL8Ii6gorCqvnkM2m3Uib1KQV9uqXm7KL6GmGmTfvPeYhdA7kGkDwG0qmkEFOeQbZErJXyvMDdPI7PfzTH6NJjB-EECCMCSFO0Pfc1htcBfM5GKe32Fd4vphh3agY8RNWrre1cbgLXpsYratxq_TGOhO2-HL2-nyFtW8774zr8dAFUw-N6q132I5HtlUJtzGd6tN906RlwFoFbZ1vFe6H1od4ho4q1UQz2ddT9P5w_3Y3zxYvj093s0WmoaB5RinhhrBiWlbTtRC8KouiyqlgJeRAOXBhqFas4JquxJoqwQRZq6qAgoPmImen6HbH2w2r1qx1shxUI_cupVdW_t84u5G1_5KsLNOjWSK42BMEn94Ve_nhh-CSZ0l5Uit5SSCh2A6lg48xmOpXAYgcA5NjHHKMQ4JcghwDYz8Lx4pm</recordid><startdate>20131107</startdate><enddate>20131107</enddate><creator>Grizzi, Fabio</creator><creator>Franceschini, Barbara</creator><creator>Biccari, Sonia Di</creator><creator>Bossi, Paola</creator><creator>Chiriva-Internati, Maurizio</creator><creator>Ferrone, Soldano</creator><general>BMJ Publishing Group LTD</general><general>BioMed Central</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20131107</creationdate><title>High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors</title><author>Grizzi, Fabio ; Franceschini, Barbara ; Biccari, Sonia Di ; Bossi, Paola ; Chiriva-Internati, Maurizio ; Ferrone, Soldano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1724-2206e03759f5d886f977f4283914126168e2ca376c2b8d2a8380daf71761c6843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Immunotherapy</topic><topic>Liver cancer</topic><topic>Lymphocytes</topic><topic>Poster Presentation</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grizzi, Fabio</creatorcontrib><creatorcontrib>Franceschini, Barbara</creatorcontrib><creatorcontrib>Biccari, Sonia Di</creatorcontrib><creatorcontrib>Bossi, Paola</creatorcontrib><creatorcontrib>Chiriva-Internati, Maurizio</creatorcontrib><creatorcontrib>Ferrone, Soldano</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grizzi, Fabio</au><au>Franceschini, Barbara</au><au>Biccari, Sonia Di</au><au>Bossi, Paola</au><au>Chiriva-Internati, Maurizio</au><au>Ferrone, Soldano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><date>2013-11-07</date><risdate>2013</risdate><volume>1</volume><issue>S1</issue><spage>P264</spage><epage>P264</epage><pages>P264-P264</pages><artnum>P264</artnum><issn>2051-1426</issn><eissn>2051-1426</eissn><abstract>Malignant transformation of cells is associated with downregulation of HLA class I APM components in most of the tumors. These defects are clinically relevant, since they are frequently associated with the clinical course of the disease. Only in a few tumors malignancy is associated with the upregulation of HLA class I antigens. Among them is hepatocellular carcinoma (HCC). The frequency of HLA class I APM component upregulation and its clinical significance in HCC are not known. These topics were investigated in the present study, since the resulting information may contribute to assess the therapeutic efficacy of T cell-based immunotherapy for the treatment of HCC. Twenty-one surgically resected primary HCC tumors and autologous adjacent non-malignant tissues were stained with a unique panel of monoclonal antibodies which recognize HLA class I APM components. The staining patterns of the malignant tumors were compared to those of the autologous non malignant tissues. To assess the functional significance of changes in HLA class I APM component expression in HCC tumors, the results of immunohistochemical staining were correlated with the extent of CD8+ cytotoxic T-lymphocyte infiltrate, quantified with a computer-aided image analysis system. In all the HCC tumors, malignant hepatocytes expressed high levels of HLA class I APM components. In contrast these molecules were not detected in normal hepatocytes, although they displayed a low expression in some apparently normal hepatocytes adjacent to the HCC tumor. The HLA class I APM component upregulation in HCC was associated with the extent of CD8+ T cell infiltrate, although this association did not reach the level of statistical significance. Our results corroborate the information in the literature about the lack of HLA class I antigen expression in hepatocytes. Furthermore our study shows for the first time that APM components are also not detectable in normal hepatocytes. Lastly our study shows that HLA class I APM component upregulation is very frequent in HCC. Its association with T cell infiltrate, although not statistically significant, is compatible with the possibility that HCC cells are recognized by CD8+ T cells. If so, HCC should represent an attractive target to apply T cell-based immunotherapy.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1186/2051-1426-1-S1-P264</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2051-1426 |
ispartof | Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P264-P264, Article P264 |
issn | 2051-1426 2051-1426 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3991183 |
source | BMJ Open Access Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Immunotherapy Liver cancer Lymphocytes Poster Presentation Tumors |
title | High frequency of HLA class I antigen processing machinery (APM) component upregulation in primary hepatocellular carcinoma tumors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A48%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20frequency%20of%20HLA%20class%20I%20antigen%20processing%20machinery%20(APM)%20component%20upregulation%20in%20primary%20hepatocellular%20carcinoma%20tumors&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Grizzi,%20Fabio&rft.date=2013-11-07&rft.volume=1&rft.issue=S1&rft.spage=P264&rft.epage=P264&rft.pages=P264-P264&rft.artnum=P264&rft.issn=2051-1426&rft.eissn=2051-1426&rft_id=info:doi/10.1186/2051-1426-1-S1-P264&rft_dat=%3Cproquest_pubme%3E2638096901%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638096901&rft_id=info:pmid/&rfr_iscdi=true |